These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 17255285)

  • 21. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
    Xu H; Krystal GW
    Clin Cancer Res; 2010 Sep; 16(17):4392-400. PubMed ID: 20732961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
    Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
    Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
    Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
    Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
    Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
    Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
    Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
    Liang SB; Yang XZ; Trieu Y; Li Z; Zive J; Leung-Hagesteijn C; Wei E; Zozulya S; Coss CC; Dalton JT; Fantus IG; Trudel S
    Clin Cancer Res; 2011 Jul; 17(14):4693-704. PubMed ID: 21632854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
    Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
    Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
    Yin S; Dong Y; Li J; Fan L; Wang L; Lu J; Vang O; Hu H
    Apoptosis; 2012 Apr; 17(4):388-99. PubMed ID: 22179721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
    Khan SB; Maududi T; Barton K; Ayers J; Alkan S
    Br J Haematol; 2004 Apr; 125(2):156-61. PubMed ID: 15059137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bcl-2 family proteins are essential for platelet survival.
    Zhang H; Nimmer PM; Tahir SK; Chen J; Fryer RM; Hahn KR; Iciek LA; Morgan SJ; Nasarre MC; Nelson R; Preusser LC; Reinhart GA; Smith ML; Rosenberg SH; Elmore SW; Tse C
    Cell Death Differ; 2007 May; 14(5):943-51. PubMed ID: 17205078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
    Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
    Neri P; Yasui H; Hideshima T; Tassone P; Raje N; Catley LP; Ishitsuka K; Blotta S; Kiziltepe T; Ocio EM; Fulciniti M; Kanekal S; Elliott GT; Munshi NC; Anderson KC
    Br J Haematol; 2006 Jul; 134(1):37-44. PubMed ID: 16803565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.